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AbstrAct
Objective Detection of subclinical cardiovascular disease 
(CVD) has significant impact on the management of type 
2 diabetes. We examined whether the assessment of 
diabetic retinopathy (DR) is useful for identifying patients at 
a higher risk of having silent CVD.
Research design and methods Prospective case–control 
study comprising 200 type 2 diabetic subjects without history 
of clinical CVD and 60 age- matched non- diabetic subjects. 
The presence of subclinical CVD was examined using two 
parameters: (1) calcium coronary score (CACs); (2) composite 
of CACs >400 UA, carotid plaque ≥3 mm, carotid intima–
media thickness ratio >1, or the presence of ECG changes 
suggestive of previous asymptomatic myocardial infarction. 
In addition, coronary angio- CT was performed. DR was 
assessed by slit- lamp biomicroscopy and retinography.
Results Type 2 diabetic subjects presented higher CACs 
than non- diabetic control subjects (p<0.01). Age, male 
gender, and the presence of DR were independently 
related to CACs >400 (area under the receiver operating 
characteristic curve (AUROC) 0.76). In addition, an inverse 
relationship was observed between the degree of DR and 
CACs <10 AU. The variables independently associated 
with the composite measurement of subclinical CVD 
were age, diabetes duration, the glomerular filtration rate, 
microalbuminuria, and the presence of DR (AUROC 0.71). 
In addition, a relationship (p<0.01) was observed between 
the presence and degree of DR and coronary stenosis.
Conclusions The presence and degree of DR is 
independently associated with subclinical CVD in type 
2 diabetic patients. Our results lead us to propose a 
rationalized screening for coronary artery disease in type 2 
diabetes based on prioritizing patients with DR, particularly 
those with moderate–severe degree.
InTROduCTIOn
Diabetes mellitus (DM) is one of the leading 
causes of mortality and major morbidities, 
including cardiovascular disease (CVD), 
kidney failure, lower limb amputation, and 
blindness. In fact, diabetic complications 
account for much of the social and financial 
burden of diabetes.1 2
significance of this study
What is already known about this subject?
 ► Diabetic retinopathy is associated to cardiovascular 
events in diabetic population.
What are the new findings?
 ► Diabetic retinopathy is a powerful and independent 
risk factor for identifying diabetic subjects with sub-
clinical cardiovascular disease.
 ► The presence of diabetic retinopathy confers a higher 
risk of subclinical cardiovascular disease than factors 
contained in contemporary risk equations such as 
blood pressure, low- density lipoprotein (LDL) choles-
terol and HbA1c.
 ► There is a clear relationship between the presence and 
degree of diabetic retinopathy and coronary stenosis.
How might these results change the focus of 
research or clinical practice?
 ► The presence and degree of diabetic retinopathy 
should be considered a better tool for identifying type 
2 diabetic subjects at risk of cardiovascular disease 
than the traditional risk factors.
 ► Type 2 diabetic patients with diabetic retinopathy and 
in particular those patients with moderate–severe 
degree represent a good target population for a cost- 
effective cardiovascular screening.
 ► The detection and grading of diabetic retinopathy per-
mit us to identify a high- risk subset of diabetic pop-
ulation who might benefit most from tight control of 
cardiovascular risk factors. In addition, given that these 
patients are more prone to develop cardiovascular 
disease, they could be used to enrich the cohorts for 
future intervention trials, thus reducing sample size, 
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Patients with diabetes generally have a greater extent 
of atherosclerosis with a higher prevalence of multivessel 
coronary artery disease (CAD) and infarction compared 
with the non- DM population.3 4 Once CAD manifests 
clinically, diabetic patients continue to have a worse prog-
nosis compared with non- diabetic patients, both during 
acute ischemic events and during long- term follow- up.5 
However, the increase in CVD risk is not homogeneous 
in patients with DM. In fact, a significant number of these 
patients will never experience CV complications, and 
current guidelines consistently advise against the routine 
use of prophylactic aspirin in patients with DM.6 7 There-
fore, the early identification of diabetic patients at risk of 
developing CVD remains a challenge.8 9
The high prevalence of type 2 diabetes precludes imple-
menting a generalized screening for CVD in asymptom-
atic patients.6 7 On the other hand, the traditional risk 
factors associated with diabetes (ie, hypertension, dyslip-
idemia, obesity) are estimated to contribute in less than 
40% of CV events. In fact, these factors are not useful for 
identifying the coronary asymptomatic patients in which 
the screening could be cost- effective.8 9 Therefore, cheap 
and routinely available measures that identify those 
patients at high risk of developing CVD are needed.
Carotid ultrasound to measure carotid intima–media 
thickness (CIMT) and a coronary artery calcium scan 
to quantify coronary calcification have been used as 
non- invasive techniques to identify subclinical athero-
sclerosis.10 CIMT has been widely used as a marker to 
identify subclinical atherosclerosis, as increased CIMT 
has been associated with a high prevalence of CAD and 
future CV events.3 A recent study has found that carotid 
plaque is predictive of underlying silent coronary athero-
sclerosis prevalence, severity, and extent in asymptomatic 
type 2 diabetic patients.11 Extensive data indicate a close 
relationship between the coronary artery calcium score 
(CACs) and clinical coronary events among individuals 
with and without diabetes.12–15 In addition, it has been 
shown that the prognostic significance of elevated CACs 
in predicting coronary events appears to be greater in 
patients with diabetes than in those without diabetes, 
and it can further enhance the predictions provided by 
established risk models.15 16 Moreover, the CACs has been 
related to moderate to large perfusion defects assessed by 
scintigraphy.4 For all these reasons, the Imaging Council 
of the American College of Cardiology concluded that 
CAC screening is the most sensitive risk stratification tool 
among asymptomatic persons with diabetes.17 Patients 
are typically stratified by Agatston units (AU), yielding 
a CACs <100 (low risk), 100 to 400 (moderate risk), 
and >400 (high risk). Notably, the finding of a CACs of 
<10 AU may facilitate risk stratification by enabling the 
identification of people at very low risk within the overall 
high- risk population of diabetic patients.18 In this regard, 
it should be noted that the absence of coronary calcium 
portends a remarkably favorable prognosis despite the 
presence of DM, with no patients experiencing adverse 
cardiac events during 5 years of follow- up.15 Nevertheless, 
widespread screening for silent CAD in diabetes cannot 
be recommended at this time19 and, consequently, the 
identification of a more targeted population in which the 
CACs would be more cost- efficient seems warranted.
Emerging evidence indicates that microangiopathy 
is independently associated with an increased risk of 
CV events in diabetic patients.20 A recent population- 
based cohort study showed that the cumulative burden 
of microvascular disease increases the risk of future 
CVD among individuals with type 2 diabetes.21 However, 
whereas microalbuminuria and macroalbuminuria are 
frequently included among the risk factors in the studies 
addressed to evaluate CV events, the presence and degree 
of diabetic retinopathy (DR) is often missing.
On this basis, the main aim of the present study was to 
determine whether the assessment of DR could help in 
identifying those in the diabetic population who should 
be candidates for CACs assessment. Since the screening 
of DR is an essential part of diabetes care, this approach 
would not increase the economic burden associated with 
diabetes management. In addition, the usefulness of DR 
in identifying subclinical CVD measured by the composite 
of a CACs >400, carotid plaque ≥3 mm, CIMT >1, or the 
presence of ECG changes suggestive of previous asymp-
tomatic myocardial infarction (MI) was also examined. In 
the present work, we show the first results of the baseline 
data of the PRECISED study which is mainly addressed to 
further clarify the impact of the presence and degree of 
microangiopathy on CV events in type 2 diabetic patients.
ReseaRCH desIgn and meTHOds
study design, data source, and patient enrollment
This was a prospective case–control study comprising a 
total of 200 type 2 diabetic subjects with no history of 
clinical CVD and 60 non- diabetic subjects matched by 
age (control group) (PRECISED study:  ClinalTrial. gov 
NCT02248311).
The inclusion criteria were (1) age from 50 to 79 
years and (2) a history of type 2 diabetes diagnosed at 
least 1 year prior to the day of screening. The exclusion 
criteria were (1) a medical history of a CV event, (2) type 
1 diabetes, (3) any contraindication for the performance 
of PET/CT or MRI, and (4) any concomitant disease 
associated with a short life expectancy.
The subjects were recruited from the Outpatient 
Diabetic Clinic of Vall d’Hebron Hospital and the Primary 
Healthcare centers within its catchment area (North 
Barcelona). A total of 2631 clinical records of subjects 
with type 2 diabetes were reviewed: 1912 did not meet 
the inclusion criteria, leaving 719 eligible for screening; 
out of these, 200 subjects with type 2 diabetes agreed to 
participate in the study. A total of 60 age- matched non- 
diabetic subjects without a history of CVD served as a 
control group. These individuals were recruited from the 
same Primary Healthcare centers and most were relatives 
of diabetic subjects. A flowchart showing the recruitment 
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Classic risk factors
Anthropometric measurements and classical risk factors
Clinical data were obtained on the first visit by an endo-
crinologist. Anthropometric data were obtained by stan-
dardized protocols at the same visit. Weight and height 
were measured with a balance with a fixed stadiometer 
to determine the body mass index (BMI). Hypertension 
was defined as systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg, or when patients 
were under treatment with antihypertensive agents.
A history of smoking habits (non- smoker/current 
smoker/ex- smoker) was recorded. Smokers who stopped 
smoking ≥1 year prior to recruitment were considered 
ex- smokers.
Dyslipidemia was defined by the use of lipid- lowering 
drugs, decreased values of high- density lipoprotein (HDL) 
cholesterol (men <0.9 mmol/L, women <1.0 mmol/L), 
or by at least one increased value of total cholesterol 
(>5.2 mmol/L), low- density lipoprotein (LDL) choles-
terol (>4.3 mmol/L), or triglycerides (>1.7 mmol/L). 
Framingham and United Kingdom Prospective Diabetes 
Study- coronary heart disease (UKPDS- CHD) were calcu-
lated as described elsewhere.22
Fundus examination
DR was evaluated by experienced ophthalmologists in 
mydriasis using slit- lamp biomicroscopy and retinog-
raphy with the same camera (Topcon- DRI- OCT- 
TRITON). The examiners classified DR according to 
the International Clinical Diabetic Retinopathy Disease 
Severity Scale23: (1) no apparent retinopathy, (2) mild 
non- proliferative retinopathy (NPDR), (3) moderate 
NPDR, (4) severe NPDR, and (5) proliferative diabetic 
retinopathy (PDR).
Laboratory tests
A venous blood sample was collected from the antecu-
bital vein, separated by centrifugation (2000×g at 4°C for 
20 min) and frozen at −80°C for batched storage and anal-
ysis. Glycosylated hemoglobin was determined by the Cobas 
B 101 (Roche) system. The remaining biochemical param-
eters were measured using an Olympus AU5400 automatic 
biochemistry analyzer (Olympus, Tokyo, Japan).
assessment of subclinical CVd
Subclinical CVD was defined as the composite of a CACs 
>400, carotid plaque ≥3 mm, or CIMT >1. The presence 
of ECG changes suggestive of previous asymptomatic 
MI (Minnesota codes 1.1. and 1.2) was also considered 
subclinical CVD.
Electrocardiogram
A 12- lead ECG was taken after the patient had been lying 
down for at least 5 min. The ECG was evaluated by a 
cardiologist.
Carotid ultrasonography
All study participants underwent a standard echo- color 
Doppler examination of the extracranial carotid arteries 
(common carotid artery, internal and external carotid 
artery) by means of a high- frequency linear probe (vivid 
7- GE and vivid 9, Medical Systems, GE Healthcare, with 
linear probe 7 MHz).
Conventional ultrasound (B- mode and color Doppler) 
was used to measure common IMT and to identify the 
presence of carotid plaques according to the Mannheim 
consensus.24 Extracranial carotid arteries were explored 
axially and longitudinally. We measured the IMT of the 
far wall of the common carotid artery at the level of 1 cm 
proximal to the bifurcation bilaterally. We used the mean 
value obtained from three measurements for our anal-
ysis. Frequency of carotid plaques was defined as the 
presence of plaques in any of the explored territories. 
The assessment of all the measurements and the perfor-
mance of the ultrasound studies were performed by two 
researchers (TG- A and LG), who were blinded to the 
conditions of the participants.
CT-CAC scanning
An ECG synchronized prospective non- enhanced cardiac 
CT was performed with Siemens Biograph mCT 64 s 
equipment. The calcium score was analyzed using semi- 
automatic methodology with “Syngo.Via” cardiac CT 
software, the global and individual Agatston score for 
coronary vessels being calculated. Patients were classi-
fied by AU as low risk (<100 AU), moderate risk (100–400 
AU), or high risk (>400 AU).18
Coronary angio-CT
After patient preparation with beta blockers for 
decreased heart rate, and nitroglycerin for vasodilatation 
if required, an ECG synchronized prospective contrast- 
enhanced coronary CT was performed with Siemens 
Biograph mCT 64 s equipment. Automatic coronary 
vessel extraction of all coronary vessels with visual anal-
ysis of coronary stenosis was performed by researchers 
blind to the patient’s condition with “Syngo.Via” cardiac 
CT software as described elsewhere.25
statistical analysis
The categorical variables are presented as percentages. 
For the quantitative variables, the mean and SD are 
displayed, except for triglycerides, lipoprotein (a), and 
homocysteine in which median and range were used. 
Differences among groups were assessed using the χ2 
test for qualitative variables, while t- test quantitative vari-
ables with a normal distribution, and non- parametric 
tests were used for those quantitative variables without a 
normal distribution.
Diabetic subjects were divided into two groups: those 
with calcium scores higher and lower than 400 AU. 
Logistic regression analysis to predict a CACs higher 
than 400 AU was performed using the variables that were 
significant at the univariant analysis. ROC curves were 
calculated and the χ2 test for ROC area comparison was 
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Table 1 Characteristics of subjects with type 2 diabetes and non- diabetic control subjects
Type 2 diabetes (n=186) Control group (n=57) P value
Sex (woman) (n, %) 107 (57.53%) 37 (64.91%) 0.32
Ethnicity (Caucasian n, %) 178 (95.7%) 56 (98.25%) 0.64
Age (years) 65.7±6.47 66.02±6.63 0.75
BMI (kg/m2) 30.25±4.9 26.83±4.77 <0.00001
Waist circumference (cm) 103.9±13.53 91.2±13.92 <0.00001
Smoking 0.59
  No (n, %) 99 (53.23%) 34 (59.65%)
  Current smoker (n, %) 25 (13.44%) 7 (12.3%)
  Ex- smoker (n, %)   62 (33.33%)   15 (26.32%)
CV family history (n, %)   22 (11.83%)   8 (14.04%) 0.65
Hypertension (n, %)   134 (72.04%)   28 (49.12%) 0.001
Use of ARB/ACEi (n, %)   118 (63.44%)   18 (31.58%) <0.0001
Dyslipidemia (n, %)   148 (78.57%)   25 (43.86%) <0.00001
Use of statins (n, %)   133 (71.51%)   19 (31.67%) <0.00001
Use of ezetimibe (n, %)   10 (5.38%)   0 (0%) 0.074
HbA1c (%)   7.43±1.18   5.55±0.31 <0.00001
HbA1c (mmol/mol)   57.85±12.96   37.12±3.31
Creatinine (mg/dL)   0.82±0.24   0.76±0.19 0.76
GFR mL/min   81.76±16   85.58±10.88 0.09
AST (IU/L)   25.51±15.71   23.48±5.73 0.34
ALT (IU/L)   25.94±16.88   21.12±10.55 0.043
GGT (IU/L)   44.46±71.82   31.04±29.77 0.17
Data are expressed as % or mean±SD.
ACEi, ACE inhibitors; ALT, alanine transaminase; ARB, angiotensin receptor blockers; AST, aspartate aminotransferase; BMI, body mass 
index; CV, cardiovascular; GFR, glomerular filtration rate; GGT, gamma- glutamyl transferase.
with a logarithmic transformation of the microalbumin-
uria:creatinine ratio.
The differences between diabetic subjects with the 
combined endpoint defined above and those without it 
were assessed. Selected variables that were significant at 
the univariate analyses were used to predict the combined 
endpoint by forward stepwise selection method in a 
binary logistic regression analysis. ROC curves were 
calculated. The area under the receiver operating char-
acteristic curves (AUROCs) for the UKPDS- CHD and 
Framingham risk scores for predicting the presence of 
the combined endpoint and the effect of the addition of 
DR and/or microalbuminuria were calculated.
Significance was accepted at the level of p value <0.05 
for all the analyses. Statistical analyses were performed 
with the Stata statistical package.
ResulTs
Clinical characteristics
The general characteristics as well as the main labora-
tory findings in subjects with type 2 diabetes and non- 
diabetic controls are shown in table 1. We did not find 
any significant difference between groups regarding 
age, gender, ethnicity, smoking habit, family history of 
CVD, or in laboratory parameters of kidney function 
(creatinine and glomerular filtration rate (GFR), aspar-
tate aminotransferase (AST) and gamma- glutamyl trans-
ferase (GGT). Subjects with type 2 diabetes presented 
a significantly higher BMI and waist circumference, as 
well as a higher prevalence of hypertension and dyslipid-
emia. Therefore, as expected, significantly more subjects 
were treated with angiotensin receptor blockers, ACE 
inhibitors, and statins in the diabetic group in compar-
ison with non- diabetic controls. As expected, HbA1c 
was significantly higher in the diabetic population than 
in control subjects. We also found significantly higher 
levels of alanine transaminase (ALT) in diabetic subjects 
in comparison with controls.
The specific characteristics of subjects with diabetes are 
displayed in online supplementary table S1. In summary, 
the type 2 diabetic patients included in the study exhib-
ited a long- term duration of diabetes with relatively 
good metabolic control (HbA1c: 57.85±12.56 mmol/mol 
(7.43%±1.18%)). Around 60% were under combined 
treatment with metformin plus insulin or insulin alone, 
and up to 30% presented at least one microangiopathic 
complication. One out of 200 included patients (0.5%) 
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Table 2 Characteristics of subjects with type 2 diabetes according to the calcium score
Calcium score <400 n=137 Calcium score ≥400 n=41 P value
Sex (woman) (n, %) 85 (62.04%) 18 (43.90%) 0.039
Age (years) 64.83±6.69 68.24±4.83 0.002
BMI (kg/m2) 30.01±5.02 31.42±4.62 0.11
Diabetes duration (years) 13.60±9.17 16.54±9.36 0.075
Waist circumference 102.87±13.81 108.07±12.86 0.034
Smoking 0.69
  No 76 (55.47%) 19 (46.34%)
  Current smoker 20 (14.60%) 5 (12.20%)
  Ex- smoker (n, %) 41 (29.93%) 17 (41.46%)
Hypertension (n, %) 94 (68.61%) 33 (80.49%) 0.14
Dyslipidemia (n, %) 110 (80.29%) 32 (78.05%) 0.75
HbA1c (%) 7.41±1.21 7.42±1.08 0.97
HbA1c (mmol/mol) 57.58±13.26 57.64±11.8
Total cholesterol (mmol/L) 4.79±0.96 4.74±0.84 0.77
HDL cholesterol (mmol/L) 1.31±0.32 1.2±0.29 0.051
LDL cholesterol (mmol/L) 2.72±0.81 2.72±0.70 0.97
Triglycerides (mmol/L) 1.47 (0.64–5.68) 1.78 (0.64–4.55) 0.14
Homocysteine (µmol/L) 10.9 (5.8–37.6) 14 (6.3–127) 0.005
Lipoprotein (a) (mg/dL) 8.93 (1–162.9) 6.89 (1–129) 0.64
GFR (mL/min) 82.32±16.66 79.37±16.35 0.32
Creatinine (mg/dL) 0.82±0.36 0.87±0.24 0.45
Albumin/:creatinine ratio
  <30 mg/g (n, %) 88 (64.71%) 27 (65.85%) 0.37
  30–300 mg/g (n, %) 41 (30.37%) 10 (24.39%)
  >300 mg/g (n, %) 6 (4.44%) 4 (9.76%)
Log albumin:creatinine ratio 1.28±0.64 1.37±0.72 0.45
Retinopathy (n, %) 27 (22.13%) 17 (39.02%) 0.014
  NPDR 26 16
   Mild 14 8
   Moderate 7 8
   Severe 5 0
  PDR 4 1
Neuropathy (n, %) 21 (15.33%) 11 (26.83%) 0.09
Data are expressed as %, mean±SD, or median and (range).
BMI, body mass index; GFR, glomerular filtration rate; HDL, high- density lipoprotein; LDL, low- density lipoprotein; NPDR, non- 
proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
dR is related to the CaCs
The distribution of control and diabetic subjects, taking 
into account the CACs, is shown in online supplementary 
table S2. As expected, type 2 diabetic patients presented 
higher CACs than non- diabetic control subjects. Among 
type 2 diabetic patients, gender, age, waist circumference, 
serum levels of homocysteine, and the presence of DR were 
significantly different in those patients with a CACs ≥400 AU 
in comparison with patients with <400 AU (table 2).
The logistic regression model, which included the 
variables with statistical significance in the univariate 
study, showed that only age, gender, and the presence 
of DR were independently related to a CACs >400 AU 
(table 3A). The model for identifying type 2 diabetic 
subjects with a CACs >400 showed an AUROC of 0.77 
(95% CI 0.72 to 0.83; p<0.00001).
We also observed an inverse relationship between the 
degree of DR and a CACs <10 AU. In this regard, 93.9% 
of patients with no or only mild DR presented a CACs 
<10 whereas this percentage was as low as 6.1% in those 
patients with moderate–severe DR.
Relationship between the CaCs and coronary stenosis
Type 2 diabetic patients presented a significantly higher 
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Table 3 (A) Results of the logistic regression analysis for predicting the presence of a calcium coronary score (CACs) 
≥400 AU in subjects with type 2 diabetes. (B, C) Results of the logistic regression analysis for predicting the presence of 
subclinical cardiovascular disease (CVD) in subjects with type 2 diabetes assessed by the combined endpoint (CACs ≥400 AU, 
carotid plaque ≥3 mm, carotid intima–media thickness >1, or ECG changes suggestive of previous asymptomatic myocardial 
infarction). Variables that were significant at a p value <0.05 in the univariate analysis of online supplementary table S3 
(comparison between the presence or not of the combined endpoint) were entered in the model as independent variables 
(age, diabetes duration, hypertension, homocysteine, glomerular filtration rate (GFR), the presence of microalbuminuria and/
or diabetic retinopathy (DR)), adjusting for gender and dyslipidemia. A forward stepwise selection method was used with a 
significance level of 0.05. In table 3C, the same analyses have been performed but DR was classified into no- DR or mild and 
moderate to severe DR/proliferative DR.
A
Coefficient SE OR (95% CI) P value
Age (years) 0.112 0.037 1.12 (1.04 to 1.21) 0.002
Gender (M/F) −1.14 0.407 0.32 (0.14 to 0.71) 0.005
Homocysteine (µmol/L) 0.063 0.036 1.07 (0.99 to 1.14) 0.084
DR (no/yes) 0.898 0.412 2.46 (1.11 to 5.51) 0.029
Constant −9.189 2.462
Dependent variable: CACs ≥400 AU. Independent variables included in the model: age, gender, waist circumference, homocysteine, and DR 
(no/yes).
B
Age (years) 0.077 0.027 1.06 (1.02 to 1.11) 0.005
DR and/or microalbuminuria 0.011
Microalbuminuria (no/yes) 0.944 0.458 2.70 (1.05 to 6.30)
DR (no/yes) 0.932 0.523 2.54 (0.91 to 7.08)
Microalbuminuria and DR 1.199 0.621 3.32 (0.98 to 11.20)
Constant −4.854 1.81
Dependent variable: combined endpoint. Independent variables included in the model: age, gender, diabetes duration, GFR, homocysteine, 
hypertension (no/yes), dyslipidemia (no/yes), and the presence of microalbuminuria and/or DR (no/yes).
C
Age (years) 0.077 0.028 1.06 (1.02 to 1.11) 0.006
DR and/or microalbuminuria 0.001
Microalbuminuria 0.816 0.407 2.26 (1.02 to 5.02)
DR (no–mild/moderate–severe) 2.144 1.096 8.53 (1.05 to 69.12)
Microalbuminuria and DR 2.202 1.096 9.04 (1.05 to 77.57)
Constant −4.873 1.842
Dependent variable: combined endpoint. Independent variables included in the model: age, gender, diabetes duration, GFR, homocysteine, 
hypertension (no/yes), dyslipidemia (no/yes), and the presence of microalbuminuria and/or DR (no or mild /moderate to severe).
least in one coronary artery) than non- diabetic control 
subjects (24.3% vs 9.1%; p=0.03). Online supplementary 
figure S2 displays the localization of these stenoses in the 
coronary arteries.
As expected, we found a clear relationship between 
the CACs and the presence of coronary stenosis in both 
diabetic and non- diabetic control subjects (figure 1A). 
Diabetic subjects with coronary stenosis presented a 
significantly higher CACs (AU) than diabetic subjects 
without coronary stenosis (337 (95% CI 10 to 2236) vs 5 
(95% CI 0 to 293); p<0.0001). Also, a clear relationship 
between the presence and degree of DR and the presence 
of one or more coronary stenoses was found (figure 1B).
subclinical CVd
The presence of subclinical CVD assessed by the 
combined endpoint was higher in type 2 diabetic patients 
than in the control group (65.7% vs 44%; p=0.05). The 
main clinical characteristics of type 2 diabetic patients 
according to the presence or absence of the combined 
endpoint is displayed in online supplementary table 3. 
Type 2 diabetic patients with the combined endpoint 
were older, presented longer diabetes duration, more 
frequent hypertension, higher homocysteine levels, 
higher levels of creatinine, a lower GFR, higher microal-
buminuria levels, and a higher frequency of DR. In addi-
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Figure 1 (A) Calcium coronary score (CACs, AU) in subjects 
with coronary stenosis (black columns) and without coronary 
stenosis (white columns). Data are median (95% CI 5% to 
95%). (B) Association between coronary stenosis and the 
presence and degree of diabetic retinopathy (DR). NPDR, 
non- proliferative diabetic retinopathy; PDR, proliferative 
diabetic retinopathy.
a higher prevalence of subclinical CVD assessed by the 
combined endpoint in comparison with patients with 
mild DR or the absence of DR (91.3% vs 60.8%; p=0.004).
The logistic regression model in which DR was intro-
duced as a categorical variable (yes/no) showed that 
DR was not an independent variable accounting for the 
combined endpoint (table 3B). However, when DR was 
introduced as absence–mild DR versus moderate–severe, 
it was strongly associated with the combined endpoint 
(OR 8.53 (95% CI 1.05 to 69.12)) (table 3C). The 
AUROC of this model for identifying subclinical CVD 
using the combined endpoint was 0.69 (95% CI 0.61 to 
0.76; p<0.05). When, in the same model, microalbumin-
uria was added to the DR categorized as moderate–severe 
versus no or mild DR, the strength of the association 
increased (9.04 (95% CI 1.05 to 77)) as well as the 
AUROC (0.72 (95% CI 0.64 to 0.78; p<0.05)).
The probability of having a CACs ≥400 AU, carotid 
plaque ≥3 mm, CIMT >1, and the composite endpoint 
according to the presence and degree of DR is repre-
sented in online supplementary table 4. The presence of 
DR significantly increases the risk of CACs ≥400 AU and 
the composite endpoint.
Finally, the discrimination abilities of the United 
Kingdom Prospective Diabetes Study (UKPDS) and Fram-
ingham cardiovascular risk scores to predict the combined 
endpoint of subclinical cardiovascular disease, adding DR 
(categorized as either “yes or no” or “moderate–severe vs 
no or mild DR”) alone or in combination with microal-
buminuria, were calculated and compared employing the 
AUROC. We found that it was only when DR was catego-
rized as moderate to severe versus no or mild DR that the 
AUROC increased significantly (table 4).
dIsCussIOn
The present study provides evidence that DR is a powerful 
and independent risk factor for identifying diabetic 
subjects with subclinical CVD. In fact, we have found 
that the assessment of DR is a good and independent 
predictor of both a CACs >400 AU and the composite of 
a CACs >400 AU, carotid plaque ≥3 mm, and CIMT >1. In 
addition, a clear relationship between the presence and 
degree of DR and coronary stenosis was found. These 
findings suggest that type 2 diabetic subjects with DR 
represent a subset of patients at very high risk of CVD 
who need a specific program aimed at reducing CV risk 
factors, optimizing metabolic control, and providing a 
periodic assessment of CVD. It should be noted that the 
presence of DR confers a higher risk of subclinical CVD 
than factors contained in contemporary risk equations, 
such as blood pressure, LDL cholesterol, and HbA1c. 
In this regard, we have found that moderate–severe DR 
significantly increases the AUROC of the UKDPS and 
Framingham risk scores CHD in predicting the presence 
of the combined endpoint of subclinical CVD.
Consistent with our findings, previous reports have 
documented an increase in CV risk in patients with 
DR, particularly in those with advanced DR.26–29 For 
instance, de Kreutzenberg et al,30 in a large cohort of 
type 2 diabetic subjects found that DR alone or in combi-
nation with nephropathy was independently associated 
with the presence of carotid plaques, and that severity 
of microangiopathy correlates with severity of carotid 
atherosclerosis. In addition, coronary atherosclerosis 
and plaque vulnerability are more severe in patients 
with DR.31 Overall, this information suggests that CAD 
is mediated by microvessel damage within the arterial 
wall (the vasa vasorum) induced by diabetes.32 Recent 
evidence indicates that in subjects with type 2 diabetes, 
the vasa vasorum presents evolutionary changes similar 
to those observed in the retina: an initial stage in which 
endothelium dysfunction and loss of capillaries predom-
inates,33 and more advanced stages in which ischemia 
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Table 4 Comparisons between UKPDS- CHD (CHD=coronary heart disease) (A) and Framingham risk scores (B) with and 
without the addition of microalbuminuria (no/yes), diabetic retinopathy (DR) (no/yes), DR+microalbuminuria, moderate–severe 
DR, and moderate–severe DR+microalbuminuria in assessing the presence of the combined endpoint
A
ROC area SE 95% CI P value
UKPDS- CHD 0.658 0.044 0.58 to 0.75
UKPDS- CHD+microalbuminuria 0.683 0.044 0.60 to 0.77 0.191
UKPDS- CHD+DR 0.687 0.045 0.60 to 0.77 0.198
UKPDS- CHD+microalbuminuria and DR 0.701 0.044 0.62 to 0.79 0.074
UKPDS- CHD+moderate–severe DR 0.729 0.041 0.65 to 0.818 0.001
UKPDS- CHD+microalbuminuria and moderate–severe DR 0.733 0.042 0.65 to 0.82 0.008
B
Framingham 0.649 0.045 0.56 to 0.78
Framingham+microalbuminuria 0.66 0.045 0.57 to 0.75 0.52
Framingham+DR 0.678 0.046 0.59 to 0.77 0.269
Framingham+microalbuminuria and DR 0.683 0.045 0.60 to 0.77 0.223
Framingham+moderate–severe DR 0.717 0.042 0.67 to 0.83 0.007
Framingham+microalbuminuria and moderate–severe DR 0.714 0.043 0.63 to 0.80 0.034
UKPDS, United Kingdom Prospective Diabetes Study.
neovascularization.33–35 This change in plaque phenotype 
results in a more inflamed and unstable plaque, favoring 
plaque rupture and a poor outcome of CV events. Thus, 
microcirculation represents a “common soil” between DR 
and CAD, and it may no longer make sense to consider 
microangiopathy and macroangiopathy as entirely sepa-
rated entities in the setting of DM.
The screening of CVD in the diabetic population 
continues to be a challenge. An analysis of pooled 
population- based studies showed that in adults older 
than 60 years without known atherosclerotic CVD at 
baseline, the CACs has a greater association with inci-
dent CHD (follow- up 11 years) and a modestly improved 
prediction of incident stroke.36 In addition, in the 
diabetic population, the severity of the CACs appeared 
to be a more important clinical prognostic indicator 
than measures of disease severity, such as insulin use, 
glycemic control, and diabetes duration.37 Our study 
further supports this concept and, in addition, shows 
a clear relationship between a CACs >400 AU and coro-
nary artery stenosis in type 2 diabetic subjects. However, 
given the high prevalence of diabetes, it is desirable to 
identify a more targeted population in which screening 
by using the CACs could be recommended. This would 
increase the cost- effectiveness of screening and avoid 
unnecessary irradiation. We found that by using simple 
clinical parameters such as age, gender, and the assess-
ment of DR, the AUROC for predicting a CACs >400 
was 0.77. In addition, CACs <10 was also associated with 
the absence of, or just mild DR.
Overall, our results point to type 2 diabetic patients with 
DR as a subset of the diabetic population at a high risk of 
having silent CVD and, in consequence, more prone to 
develop a cardiovascular outcome. However, given that the 
prevalence of DR in type 2 diabetic subjects is around 30%, 
it still remains a huge population as regards recommending 
screening for silent CVD. The high risk in those patients with 
moderate–severe DR of exhibiting subclinical CVD points 
to this specific subset of patients as the most cost- effective 
candidates for screening. Therefore, healthcare professionals 
involved in the treatment of patients with diabetes should 
contemplate those individuals with moderate–severe DR as 
a high- risk population independently of the association of 
other traditional CV risk factors.
CT angiography images of coronary artery stenosis 
provide a better prediction risk in asymptomatic type 2 
diabetics than traditional risk factors and the CACs.38 39 
Notably, we have found for the first time a relationship 
between DR and the presence of coronary stenosis assessed 
by coronary CT angiography. Patients with DR presented a 
higher proportion of having one or more coronary stenoses 
≥50% than those patients without DR (38.5% vs 20.2%). In 
addition, this proportion was even higher (50%) in those 
patients with moderate–severe NPDR and PDR.
Apart from DR, we found that microalbuminuria was 
associated with subclinical CVD assessed by the combined 
endpoint, but it was unrelated to the CACs or the presence 
of coronary stenosis. This finding suggests that microalbu-
minuria reflects a more widespread atherosclerotic process, 
whereas the presence and degree of DR might be more 
directly related to CAD. It should be noted that there is 
extensive evidence indicating that microalbuminuria is an 
independent CV risk factor and it is generally considered 
in the design and the analysis of the results of clinical trials 
on CVD performed in the diabetic population. However, 
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that could lead to a serious bias on the results obtained in 
both epidemiologic and interventional studies.
Our results underline the importance of screening for 
DR, which should be envisaged as a method for studying the 
microvasculature of the retina and its potential implications 
in vision loss, and also as a herald of other systemic compli-
cations of diabetes, including CVD. Retinal imaging has the 
significant advantage of not using ionizing irradiation and 
it is performed as routine screening in the diabetic popula-
tion. Given the alarming increase in the number of people 
with diabetes and the shortage of trained retinal specialists 
and graders of retinal photographs, an automated approach 
involving a computer- based analysis of the fundus image 
would reduce the burden of health systems in screening for 
DR.40 41 There is hence an increasing interest in the devel-
opment of automated analysis software using artificial intelli-
gence/deep neural learning for the analysis of retinal images 
in people with diabetes,41 and it is foreseeable that specific 
software will be developed to better define the cardiovascular 
risk of diabetic individuals based on the retinal structural and 
functional findings of microvessels.
The low percentage of silent MI detected by ECG in 
our cohort, 1 out 200 (0.5%), is quite surprising. In the 
UKPDS, 1 in 6 (16%) patients with newly diagnosed type 
2 diabetes had evidence of silent MI on the baseline 
surface ECG.42 In older studies, the prevalence of ECG 
abnormalities in patients with type 2 diabetes and no 
known CAD was even higher, approaching 20%.43 44 The 
low rate of silent MI in our diabetic population could not 
be attributed to low diabetes duration or a selected group 
with low diabetes- related systemic complications. In 
fact, the mean of known diabetic duration was 12 years, 
around 30% of the subjects already presented microan-
giopathic complications, and more than half required 
treatment with insulin. It should be noted that this low 
rate of ECG signs of asymptomatic ischemic heart disease 
did not mean the presence of low myocardial microan-
giopathy. In this regard, we have previously reported 
that DR was independently associated with myocardial 
perfusion defects.45 Altogether, these findings suggest 
that our population could have a high degree of protec-
tion against CV outcomes despite having a high rate of 
cardiovascular risk factors including microangiopathy. A 
Mediterranean diet and the high proportion of patients 
under treatment with statins might help explain why we 
detected a very low rate of silent MI; however, specific 
studies aimed at examining this issue are needed.
This study has several limiting factors. First, the analyses 
were restricted to individuals for whom complete informa-
tion was available, and this may have resulted in selection 
bias. Second, the results could have been affected by vari-
ables such as diet or ambient factors not considered in this 
analysis. Third, the study population was relatively small 
and the data presented are observational in nature. Finally, 
although our results suggest that the assessment of DR may 
offer a simple tool to identify very high- risk individuals with 
type 2 diabetes who are currently perceived to be at low 
absolute risk using contemporary risk models, all the risk 
algorithms (eg, QRISK, Framingham, Reynolds, UKDPS) 
are for calculating risk estimates and not for the detection 
of subclinical atherosclerosis. Therefore, further studies 
with a larger sample size are required to evaluate whether 
the addition of DR grading to conventional risk algorithms 
will confer any additional benefits.
Our findings could have both therapeutic and investiga-
tional implications. In fact, the detection and grading of DR 
permits us to identify patients at high CV risk who might, 
under current guidelines, benefit most from further lipid 
and blood glucose lowering, or it could be used to enrich 
the cohorts for future intervention trials with patients more 
prone to develop clinical outcomes, thus reducing sample 
size, duration, and the cost of studies.
In summary, the presence of DR is an independent 
predictor of CACs >400 AU, and moderate–severe DR is 
independently associated with subclinical CVD. There-
fore, the presence and degree of DR should be consid-
ered a better tool for identifying type 2 diabetic patients 
at risk of CVD than the conventional CV risk factors used 
in current risk equations. Our results have significant 
clinical implications in terms of proposing a rationalized 
screening of CAD based on prioritizing patients with DR, 
in particular those with a moderate–severe degree.
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